Press Releases

  December 7, 2017
NEW STORY CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study
  November 28, 2017
NEW STORY CEL-SCI Extends the Expiration Date of Series DD and Series EE Warrants Issued in December 2016
  November 13, 2017
NEW STORY CEL-SCI Announces Update on Arbitration against Former Clinical Research Organization
  October 10, 2017
NEW STORY CEL-SCI Granted European Patent for Multikine's Mechanism of Action in Making Tumors 'Visible' To the Immune System
  October 5, 2017
NEW STORY CEL-SCI Announces Update on Ongoing Arbitration Against Former Clinical Research Organization
  Septembe 19, 2017
NEW STORY CEL-SCI Announces $1.5 Million NIH SBIR Grant to Support Development of Rheumatoid Arthritis Vaccine
  Septembe 11, 2017
NEW STORY CEL-SCI to Present Today At the 19th Annual Rodman & Renshaw Global Investment Conference
  August 30, 2017
NEW STORY CEL-SCI to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 11, 2017
  August 29, 2017
NEW STORY CEL-SCI Extends the Expiration Date of Series DD and Series EE Warrants Issued In December 2016
  August 23, 2017
NEW STORY CEL-SCI Announces $3.5 Million Registered Direct Offering
  August 14, 2017
NEW STORY U.S. FDA Removes Clinical Hold on CEL-SCI's Phase 3 Head & Neck Cancer Trial
  August 9, 2017
NEW STORY CEL-SCI Extends the Expiration Date of Series DD Warrants Issued in December 2016
  August 9, 2017
NEW STORY CEL-SCI Corporation Reports Third Quarter Fiscal Year 2017 Financial Results
  July 6, 2017
NEW STORY CEL-SCI Extends the Expiration Date of Series DD Warrants Issued in December 2016
  June 12, 2017
NEW STORY CEL-SCI Announces Reverse Stock Split
  June 8, 2017
NEW STORY CEL-SCI Announces New Data for Its Rheumatoid Arthritis Vaccine Candidate Published in Peer Reviewed Journal
  June 7, 2017
NEW STORY CEL-SCI Extends the Expiration Date of Series DD Warrants Issued in December 2016
  June 5, 2017
NEW STORY CEL-SCI Submits FDA Response for Its Phase 3 Head and Neck Cancer Trial
  May 24, 2017
NEW STORY CEL-SCI Corporation Releases Letter to Shareholders
  May 16, 2017
NEW STORY CEL-SCI Scientist Presents At AAI - IMMUNOLOGY 2017 Meeting
  May 12, 2017
NEW STORY CEL-SCI Announces Change to the Date of Its Annual Meeting
  May 10, 2017
NEW STORY CEL-SCI Corporation Reports Second Quarter Fiscal Year 2017 Financial Results
  May 1, 2017
NEW STORY CEL-SCI Announces $1.51 Million Registered Direct Offering
  April 28, 2017
NEW STORY CEL-SCI Receives Intent to Grant Notice for New Multikine Patent from the European Patent Office
  April 24, 2017
NEW STORY CEL-SCI Corporation Releases Letter to Shareholders
  April 12, 2017
NEW STORY CEL-SCI Scientist Presents at the World Vaccine Congress
  March 9, 2017
NEW STORY CEL-SCI Announces $1.5 Million Registered Direct Offering
  March 6, 2017
NEW STORY CEL-SCI Gives Update on Partial Clinical Hold on Phase 3 Head and Neck Cancer Study with Multikine
  February 27, 2017
NEW STORY CEL-SCI Announces That the NYSE MKT Approves Plan
  February 21, 2017
NEW STORY CEL-SCI Scientist Presents New Findings for Rheumatoid Arthritis Treatment Vaccine at Conference
  February 17, 2017
NEW STORY CEL-SCI Announces $1.0 Million Registered Direct Offering
  February 9, 2017
NEW STORY CEL-SCI Corporation Reports First Quarter Fiscal 2017 Financial Results
  December 20, 2016
NEW STORY CEL-SCI Announces Closing of Public Offering and Receives Audit Opinion with Going Concern Explanation
  December 14, 2016
NEW STORY CEL-SCI Reports Fiscal 2016 Financial Results and Clinical & Corporate Developments
  December 9, 2016
CEL-SCI Reports on NYSE MKT Noncompliance Notice and Compliance Plan
  December 2, 2016
CEL-SCI Announces Pricing of $4.25 Million Public Offering of Common Stock and Warrants
  December 1, 2016
CEL-SCI Announces Proposed Public Offering of Common Stock and Warrants
  November 21, 2016
CEL-SCI Submits Response to FDA in Connection with Partial Clinical Hold on Phase 3 Clinical Trial
  November 14, 2016
CEL-SCI Reports Preclinical Data Showing LEAPS Vaccine Is Successful In Treating Rheumatoid Arthritis
  October 21, 2016
CEL-SCI Provides Update on Partial Clinical Hold on Phase 3 Clinical Trial
  September 26, 2016
CEL-SCI Reports Clinical Hold on Head and Neck Cancer Study
  September 6, 2016
CEL-SCI Announces Resignation of Its Founder for Health Reasons
  September 2, 2016
CEL-SCI Reports Monthly Patient Enrollment in August for Its Phase 3 Head and Neck Cancer Trial
  August 29, 2016
CEL-SCI Announces the Closing of its $5 Million Registered Direct Offering
  August 23, 2016
CEL-SCI Announces $5 Million Registered Direct Offering
  August 10, 2016
CEL-SCI Corporation Reports Third Quarter Fiscal Year 2016 Financial Results
  August 1, 2016
CEL-SCI Reports Monthly Patient Enrollment in July for Its Phase 3 Head and Neck Cancer Trial
  July 11, 2016
CEL-SCI Granted European Patent for Multikine Cancer Immunotherapy in Combination with Radiation and/or Chemotherapy
  July 5, 2016
CEL-SCI Reports Monthly Patient Enrollment in June for Its Phase 3 Head and Neck Cancer Trial
  June 7, 2016
CEL-SCI to Present at LD Micro Invitational
  June 1, 2016
CEL-SCI Reports Monthly Patient Enrollment in May for Its Phase 3 Head and Neck Cancer Trial
  May 31, 2016
CEL-SCI to Present At the Fifth Annual Marcum Microcap Conference
  May 24, 2016
CEL-SCI Announces the Closing of Its $5 Million Registered Direct Offering
  May 18, 2016
CEL-SCI Announces $5 Million Registered Direct Offering
  May 10, 2016
CEL-SCI Corporation Reports Second Quarter Fiscal Year 2016 Financial Results
  May 2, 2016
CEL-SCI Reports Record Monthly Patient Enrollment in April for Its Phase 3 Head and Neck Cancer Trial
  April 1, 2016
CEL-SCI Reports Monthly Patient Enrollment in March for Its Phase 3 Head and Neck Cancer Trial
  March 1, 2016
CEL-SCI Reports Monthly Patient Enrollment in February for Its Phase 3 Head and Neck Cancer Trial
  February 23, 2016
CEO Geert Kersten summarizes CEL-SCI's Phase 3 cancer immunotherapy progress in a new video interview
  February 18, 2016
CEL-SCI CEO Geert Kersten was a Featured Guest on Fox Business' Making Money with Charles Payne
  February 9, 2016
CEL-SCI Corporation Reports First Quarter Fiscal 2016 Financial Results
  February 8, 2016
CEL-SCI To Present At Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
  February 3, 2016
CEL-SCI to Present at 18TH Annual BIO CEO & Investor Conference
  February 1, 2016
CEL-SCI Reports Monthly Patient Enrollment in January for Its Phase 3 Head and Neck Cancer Trial
  January 25, 2016
CEL-SCI'S Chief Scientific Officer Discusses Cancer Immunotherapy Multikine
  January 14, 2016
CEL-SCI Corporation to Present at the Noble Financial Capital Markets' 12th Annual Investor Conference
  January 8, 2016
CEL-SCI Corporation Summarizes Significant Accomplishments in 2015 and Positive Momentum For 2016
  January 5, 2016
CEL-SCI Reports Record Year for Patient Enrollment With 75% Increase in Its Global Phase 3 Head and Neck Cancer Trial

Press Releases - 2015

Press Releases - 2014

Press Releases - 2013

Press Releases - 2012

Press Releases - 2011